Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

FIXED ASSETS

FIXED ASSETS

12 Months Ended

Dec. 31, 2021

FIXED ASSETS

FIXED ASSETS

4. FIXED ASSETS

Fixed assets consisted of the following as of December 31:


	2021		2020

Office and laboratory equipment	$	575,370	$	445,758
Computer software		4,000		4,000
Leasehold improvements		309,897		309,897
Total fixed assets		889,267		759,655
Less– accumulated depreciation and amortization		(544,776)		(403,673)
Fixed assets, net	$	344,491	$	355,982

For the years ended December 31, 2021 and 2020, the Company recorded approximately $150,000 and $141,000 of depreciation and amortization expense, respectively.